Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

Dietmar W. Siemann, Emma Mercer, Sharon Lepler, Amyn Mohammed Rojiani

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

The utility of combining the vascular targeting agents 5,6dimethyl-xanthenone-4 acetic acid (DMXAA) and combretastatin A-4 disodium phosphate (CA4DP) with the anticancer drugs cisplatin and cyclophosphamide (CP) was evaluated in experimental rodent (KHT sarcoma), human breast (SKBR3) and ovarian (OW-1) tumor models. Doses of the vascular targeting agents that led to rapid vascular shutdown and subsequent extensive central tumor necrosis were identified. Histologic evaluation showed morphologic damage of tumor cells within a few hours after treatment, followed by extensive hemorrhagic necrosis and dose-dependent neoplastic cell death as a result of prolonged ischemia. Whereas these effects were induced by a range of CA4DP doses (10150 mg/kg), the dose response to DMXAA was extremely steep; doses ≤ 15 mg/kg were ineffective and doses ≥ 20 mg/kg were toxic. DMXAA also enhanced the tumor cell killing of cisplatin, but doses > 15 mg/kg were required. In contrast, CA4DP increased cisplatin-induced tumor cell killing at all doses studied. This enhancement of cisplatin efficacy was dependent on the sequence and interval between the agents. The greatest effects were achieved when the vascular targeting agents were administered 1-3 hr after cisplatin. When CA4DP (100 mg/kg) or DMXAA (17.5 mg/ kg) were administered 1 hr after a range of doses of cisplatin or CP, the tumor cell kill was 10-500-fold greater than that seen with chemotherapy alone. In addition, the inclusion of the antivascular agents did not increase bone marrow stem cell toxicity associated with these anticancer drugs, thus giving rise to a therapeutic gain.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalInternational Journal of Cancer
Volume99
Issue number1
DOIs
StatePublished - May 1 2002
Externally publishedYes

Fingerprint

vadimezan
Cisplatin
Blood Vessels
Neoplasms
Cyclophosphamide
Necrosis
Therapeutics
Poisons
Bone Marrow Cells
Sarcoma
Pharmaceutical Preparations
Rodentia
Breast
Cell Death
Stem Cells
Ischemia
Drug Therapy
fosbretabulin

Keywords

  • Antivascular therapies
  • CA4DP
  • Cisplatin
  • Cyclophosphamide
  • DMXAA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. / Siemann, Dietmar W.; Mercer, Emma; Lepler, Sharon; Rojiani, Amyn Mohammed.

In: International Journal of Cancer, Vol. 99, No. 1, 01.05.2002, p. 1-6.

Research output: Contribution to journalArticle

@article{1ec691808f7a411faf4146b444c3d878,
title = "Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy",
abstract = "The utility of combining the vascular targeting agents 5,6dimethyl-xanthenone-4 acetic acid (DMXAA) and combretastatin A-4 disodium phosphate (CA4DP) with the anticancer drugs cisplatin and cyclophosphamide (CP) was evaluated in experimental rodent (KHT sarcoma), human breast (SKBR3) and ovarian (OW-1) tumor models. Doses of the vascular targeting agents that led to rapid vascular shutdown and subsequent extensive central tumor necrosis were identified. Histologic evaluation showed morphologic damage of tumor cells within a few hours after treatment, followed by extensive hemorrhagic necrosis and dose-dependent neoplastic cell death as a result of prolonged ischemia. Whereas these effects were induced by a range of CA4DP doses (10150 mg/kg), the dose response to DMXAA was extremely steep; doses ≤ 15 mg/kg were ineffective and doses ≥ 20 mg/kg were toxic. DMXAA also enhanced the tumor cell killing of cisplatin, but doses > 15 mg/kg were required. In contrast, CA4DP increased cisplatin-induced tumor cell killing at all doses studied. This enhancement of cisplatin efficacy was dependent on the sequence and interval between the agents. The greatest effects were achieved when the vascular targeting agents were administered 1-3 hr after cisplatin. When CA4DP (100 mg/kg) or DMXAA (17.5 mg/ kg) were administered 1 hr after a range of doses of cisplatin or CP, the tumor cell kill was 10-500-fold greater than that seen with chemotherapy alone. In addition, the inclusion of the antivascular agents did not increase bone marrow stem cell toxicity associated with these anticancer drugs, thus giving rise to a therapeutic gain.",
keywords = "Antivascular therapies, CA4DP, Cisplatin, Cyclophosphamide, DMXAA",
author = "Siemann, {Dietmar W.} and Emma Mercer and Sharon Lepler and Rojiani, {Amyn Mohammed}",
year = "2002",
month = "5",
day = "1",
doi = "10.1002/ijc.10316",
language = "English (US)",
volume = "99",
pages = "1--6",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

AU - Siemann, Dietmar W.

AU - Mercer, Emma

AU - Lepler, Sharon

AU - Rojiani, Amyn Mohammed

PY - 2002/5/1

Y1 - 2002/5/1

N2 - The utility of combining the vascular targeting agents 5,6dimethyl-xanthenone-4 acetic acid (DMXAA) and combretastatin A-4 disodium phosphate (CA4DP) with the anticancer drugs cisplatin and cyclophosphamide (CP) was evaluated in experimental rodent (KHT sarcoma), human breast (SKBR3) and ovarian (OW-1) tumor models. Doses of the vascular targeting agents that led to rapid vascular shutdown and subsequent extensive central tumor necrosis were identified. Histologic evaluation showed morphologic damage of tumor cells within a few hours after treatment, followed by extensive hemorrhagic necrosis and dose-dependent neoplastic cell death as a result of prolonged ischemia. Whereas these effects were induced by a range of CA4DP doses (10150 mg/kg), the dose response to DMXAA was extremely steep; doses ≤ 15 mg/kg were ineffective and doses ≥ 20 mg/kg were toxic. DMXAA also enhanced the tumor cell killing of cisplatin, but doses > 15 mg/kg were required. In contrast, CA4DP increased cisplatin-induced tumor cell killing at all doses studied. This enhancement of cisplatin efficacy was dependent on the sequence and interval between the agents. The greatest effects were achieved when the vascular targeting agents were administered 1-3 hr after cisplatin. When CA4DP (100 mg/kg) or DMXAA (17.5 mg/ kg) were administered 1 hr after a range of doses of cisplatin or CP, the tumor cell kill was 10-500-fold greater than that seen with chemotherapy alone. In addition, the inclusion of the antivascular agents did not increase bone marrow stem cell toxicity associated with these anticancer drugs, thus giving rise to a therapeutic gain.

AB - The utility of combining the vascular targeting agents 5,6dimethyl-xanthenone-4 acetic acid (DMXAA) and combretastatin A-4 disodium phosphate (CA4DP) with the anticancer drugs cisplatin and cyclophosphamide (CP) was evaluated in experimental rodent (KHT sarcoma), human breast (SKBR3) and ovarian (OW-1) tumor models. Doses of the vascular targeting agents that led to rapid vascular shutdown and subsequent extensive central tumor necrosis were identified. Histologic evaluation showed morphologic damage of tumor cells within a few hours after treatment, followed by extensive hemorrhagic necrosis and dose-dependent neoplastic cell death as a result of prolonged ischemia. Whereas these effects were induced by a range of CA4DP doses (10150 mg/kg), the dose response to DMXAA was extremely steep; doses ≤ 15 mg/kg were ineffective and doses ≥ 20 mg/kg were toxic. DMXAA also enhanced the tumor cell killing of cisplatin, but doses > 15 mg/kg were required. In contrast, CA4DP increased cisplatin-induced tumor cell killing at all doses studied. This enhancement of cisplatin efficacy was dependent on the sequence and interval between the agents. The greatest effects were achieved when the vascular targeting agents were administered 1-3 hr after cisplatin. When CA4DP (100 mg/kg) or DMXAA (17.5 mg/ kg) were administered 1 hr after a range of doses of cisplatin or CP, the tumor cell kill was 10-500-fold greater than that seen with chemotherapy alone. In addition, the inclusion of the antivascular agents did not increase bone marrow stem cell toxicity associated with these anticancer drugs, thus giving rise to a therapeutic gain.

KW - Antivascular therapies

KW - CA4DP

KW - Cisplatin

KW - Cyclophosphamide

KW - DMXAA

UR - http://www.scopus.com/inward/record.url?scp=0036568457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036568457&partnerID=8YFLogxK

U2 - 10.1002/ijc.10316

DO - 10.1002/ijc.10316

M3 - Article

VL - 99

SP - 1

EP - 6

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -